Researchers have developed an AI-driven platform, IDentif.AI, to create sex-specific drug combinations for treating aortic valve stenosis (AVS), a condition affecting 1 in 8 adults over 75 globally. This breakthrough, published in Science Advances, addresses the long-standing gap in cardiovascular drug development, which has historically focused on male patients, often leaving women with less effective treatments.
The study, led by researchers from the National University of Singapore (NUS Medicine) and the University of California, San Diego, utilized IDentif.AI to analyze drug combinations for AVS. The AI platform identified female-biased combinations (e.g., Y-27632/SB-203580/SD-208) and male-biased combinations (e.g., LY294002/Irosustat/TM5441), each proving more effective in their respective sexes. Notably, Losartan, an existing hypertension drug, was included in top combinations, potentially speeding up the approval of new treatments.
The team cultured valvular interstitial cells (VICs) from laboratory models in hydrogel biomaterials that mimic human heart valve conditions. Testing 59 drug combinations, they measured their ability to inhibit myofibroblast activation—a key process in AVS that causes valve stiffening and scarring.
Professor Dean Ho, co-lead of the study, emphasized the importance of sex-specific treatments: “Our work shows that men and women may need different drug combinations for optimal outcomes in diseases like AVS.” The findings could pave the way for more personalized therapies and highlight the need to consider sex as a biological variable in drug development.
The researchers plan to expand this approach to other diseases with sex-specific progression and treatment responses, leveraging hydrogel biomaterials and AI to accelerate precision medicine.
This study marks a significant step toward personalized, sex-specific healthcare, offering hope for more effective treatments for AVS and beyond. By integrating AI and advanced biomaterials, the team has opened new avenues for addressing disparities in medical research and improving patient outcomes worldwide.
Add comment